Abstract
Disease-modifying drugs (DMDs) such as interferon (IFN)-β and glatiramer acetate are often prescribed to slow disability progression in patients with multiple sclerosis (MS). However, adverse pregnancy outcomes have been reported with these medications. We report the rare occurrence of severe placental complications in a 30-yearold pregnant woman with MS who continued to take IFN-β during her first trimester. She presented at the Tawam Hospital, Al Ain, United Arab Emirates, in 2013 with early-onset fetal growth restriction. At 30 gestational weeks, she developed severe pre-eclampsia. The baby was delivered via emergency Caesarean section and was discharged at the age of two months. Continuation of IFN-β during pregnancy may have contributed to the development of placental insufficiency in this patient. Increased education regarding the risks of DMDs for pregnant patients with MS is very important to ensure successful pregnancy outcomes.
Publication Date
8-19-2016
First Page
368
Last Page
370
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
Salahudheen, Sultan M. and Begam, Muzibunnisa A.
(2016)
"Disease-Modifying Drug Possibly Linked to Placental Insufficiency : Severe placental complications in a pregnant woman with multiple sclerosis,"
Sultan Qaboos University Medical Journal: Vol. 16: 368-370.
DOI: https://doi.org/10.18295/squmj.2016.16.03.019
